The latest price target for West Pharmaceutical Servs (NYSE:WST) was reported by Keybanc on February 14, 2025. The analyst firm set a price target for $325.00 expecting WST to rise to within 12 months (a possible 44.62% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for West Pharmaceutical Servs (NYSE:WST) was provided by Keybanc, and West Pharmaceutical Servs maintained their overweight rating.

The last upgrade for West Pharmaceutical Services Inc happened on December 12, 2024 when UBS raised their price target to $390. UBS previously had a neutral for West Pharmaceutical Services Inc.

The last downgrade for West Pharmaceutical Services Inc happened on October 28, 2022 when B of A Securities changed their price target from $385 to $250 for West Pharmaceutical Services Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $470.00 to $325.00. The current price West Pharmaceutical Servs (WST) is trading at is $224.72, which is out of the analyst’s predicted range.